Thrombomodulin Mitigates the Progression of Hepatocellular Carcinoma in Steatotic Liver
Open Access
- 1 February 2026
- journal article
- research article
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-13
Abstract
Introduction: Metabolic dysfunction associated steatotic liver disease promotes intrahepatic metastasis of liver cancer, although not uniformly. However, the mechanisms underlying steatosis-induced progression of liver cancer are not well understood. Antitumor properties of thrombomodulin (TM) are unknown. We aimed to investigate whether TM contributes to the suppression of hepatocellular carcinoma (HCC) progression in the steatotic livers of mice. Methods: Mice were fed a normal or choline-deficient diet (CDD) for 4 weeks, followed by splenic injection of mouse Hepa1-6 cells. Hepatic tumors were analyzed 3 weeks after the injection. Results: CDD induced hepatic steatosis, which resulted in a hypoxic state and the downregulation of TM in the liver. CDD-induced hepatic steatosis promoted HCC progression and increased serum levels of high motility group box 1 (HMGB-1), which were suppressed by recombinant TM (rTM). However, HCC progression was not promoted in non-steatotic livers. In TM+/- mice with hepatic steatosis, of which endogenous TM was severely down-regulated, ischemia-reperfusion significantly enhanced HCC progression compared to that in wild-type mice with steatotic livers, both of which were also ameliorated by rTM. In vitro, hypoxia promoted Hepa1-6 cell motility and secretion of HMGB-1 from the Hepa1-6 cells, and the addition of HMGB-1 also enhanced the motility of the Hepa1-6 cells in the non-hypoxic state, which was suppressed by rTM and anti-HMGB-1 antibodies. Discussion: These findings suggest that hepatic steatosis has a prometastatic effect through the downregulation of TM. TM has a tumor-suppressive function via the inhibition of HMGB-1 activity. Plain Language Summary: Steatotic liver reduces the expression of TM and accelerated the progression of HCC by decreasing the capacity of TM to absorb HMGB-1. rTM may be a useful modality to prevent HCC progression in steatotic livers during hepatic surgery.Keywords
This publication has 51 references indexed in Scilit:
- Thrombomodulin expression impacts the recurrence and long‐term survival in pancreatic cancerAnnals of Gastroenterological Surgery, 2021
- NOD‐like receptor C4 Inflammasome Regulates the Growth of Colon Cancer Liver Metastasis in NAFLDHepatology, 2019
- Hypoxia mediates mitochondrial biogenesis in hepatocellular carcinoma to promote tumor growth through HMGB1 and TLR9 interactionHepatology, 2017
- Effect of ischaemic preconditioning on recurrence of hepatocellular carcinoma in an experimental model of liver steatosisBritish Journal of Surgery, 2016
- Fatty liver creates a pro‐metastatic microenvironment for hepatocellular carcinoma through activation of hepatic stellate cellsInternational Journal of Cancer, 2014
- Fatty liver disease as a predictor of local recurrence following resection of colorectal liver metastasesBritish Journal of Surgery, 2013
- Hypoxia-inducible factor 1 alpha–activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule-1/integrin β1 signaling in human hepatocellular carcinomaHepatology, 2011
- Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty ConnectionHepatology, 2010
- Ischemia/Reperfusion Accelerates the Outgrowth of Hepatic Micrometastases in a Highly Standardized Murine Model *Hepatology, 2005
- Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinomaHepatology, 1995